TRISALUS LIFE SCIENCES INC (TLSI) Stock News

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

3 Stocks With Robust Growth Outlooks Insiders Are Buying

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.

Mentions: SFD AVDL

TriSalus Life Sciences Announces Key Appointments to Board of Directors

A Look Ahead: TriSalus Life Sciences's Earnings Forecast

Crude Oil Rises 1%; Verastem Shares Slide

Mentions: DECK VSTM MRUS AKAN ...

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips TriSalus Life Sciences (NASDAQ:TLSI) just reported results for the fourth quart...

TriSalus Announces Leadership Changes

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024

TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

TriSalus Reports Q2 2024 Financial Results and Business Update

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024

TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

TriSalus Reports Q1 2024 Financial Results and Business Update

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023

TLSI stock results show that TriSalus Life Sciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update